文献速递鼻科

益生菌提取物通过诱导产IL-35树突状细胞改善小鼠鼻过敏

Probiotic extracts ameliorate nasal allergy by inducing interleukin-35-producing dendritic cells in mice.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-10-17

本研究制备婴儿双歧杆菌提取物(EBI),在变应性鼻炎(AR)小鼠模型中评估其疗效。EBI经IL-35/STAT3途径诱导产IL-10树突状细胞,进而诱导具免疫抑制功能的产IL-10 B细胞(B10细胞)。EBI滴鼻显著抑制AR小鼠搔鼻、打喷嚏及血清特异性IgE和鼻黏膜Th2细胞因子水平,提示其具有治疗AR的转化潜力。

要点

  • EBI经IL-35/STAT3诱导产IL-10树突状细胞并促进B10细胞生成。
  • EBI滴鼻显著抑制AR小鼠过敏症状及鼻黏膜Th2细胞因子。
  • EBI有望经临床前验证后转化为AR治疗手段。

核心结论

  • EBI可通过诱导B10细胞抑制变应性鼻炎,具备治疗AR及其他过敏疾病的转化潜力。

研究设计与样本

  • 基础研究:制备婴儿双歧杆菌提取物(EBI),在AR小鼠模型中评估其治疗效果。

主要发现

  • EBI经增加IL-35和STAT3磷酸化诱导产IL-10树突状细胞。
  • 产IL-10树突状细胞诱导具免疫抑制功能的B10细胞。
  • AR小鼠攻击后出现打喷嚏、鼻痒及血清特异性IgE和鼠肥大细胞蛋白酶-1升高。
  • 鼻黏膜蛋白提取物中Th2细胞因子治疗前为IL-4 67.17±10.66、IL-5 62.83±9.70、IL-13 51.00±6.69。
  • EBI滴鼻治疗后Th2细胞因子显著降低为IL-4 27.00±6.66、IL-5 23.86±4.53、IL-13 25.67±4.93(p<0.001)。

临床怎么用

  • 目前仅限小鼠模型,尚需完成规定的临床前实验和检测后再评估临床转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The therapeutic efficacy of allergic rhinitis (AR) needs to be improved. Probiotics have immunoregulatory functions. In this study we evaluated the effects of protein extracts of probiotics in the amelioration of AR. METHODS: Extracts of Bifidobacterium infantis (EBI) were prepared by lysing the live probiotics. AR mice were developed to be used to evaluate the therapeutic efficacy of EBI. RESULTS: The results show that EBI induced interleukin (IL)-10-producing dendritic cells (DCs) via increasing IL-35 and signal transducer and activator of transcription 3 (STAT3) phosphorylation. IL-10-expressing DCs induced IL-10-producing B cells (B10 cells), with the latter showing immunosuppressive functions. After challenge with specific antigens, AR mice showed sneezing, nasal itch, and increases in serum-specific immunoglobulin E (IgE) and mouse mast cell protease-1; higher levels of T helper 2 (Th2) cytokines (IL-4, 67.17 ± 10.66; IL-5, 62.83 ± 9.70; IL-13, 51.00 ± 6.69, before treatment) in nasal mucosal protein extracts, which were significantly suppressed (IL-4, 27.00 ± 6.66; IL-5, 23.86 ± 4.53; IL-13, 25.67 ± 4.93, after treatment (p < 0.001) by administration with EBI nasal drops. CONCLUSION: EBI can suppress AR via inducing B10 cells. Thus, after carrying out required preclinical experiments and tests, EBI has the translational potential to be used in the treatment of AR and other allergic diseases.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Xue JM, Ma F, An YF, et al. Probiotic extracts ameliorate nasal allergy by inducing interleukin-35-producing dendritic cells in mice. Int Forum Allergy Rhinol. 2019. PMID: 31623025. doi:10.1002/alr.22438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。